171 related articles for article (PubMed ID: 19182214)
1. The cost-effectiveness of screening for hereditary hemochromatosis in Germany: a remodeling study.
Rogowski WH
Med Decis Making; 2009; 29(2):224-38. PubMed ID: 19182214
[TBL] [Abstract][Full Text] [Related]
2. Screening blood donors for hereditary hemochromatosis: decision analysis model comparing genotyping to phenotyping.
Adams PC; Valberg LS
Am J Gastroenterol; 1999 Jun; 94(6):1593-600. PubMed ID: 10364030
[TBL] [Abstract][Full Text] [Related]
3. Searching for hereditary hemochromatosis.
Laudicina RJ
Clin Lab Sci; 2006; 19(3):174-83. PubMed ID: 16910235
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of screening for hereditary hemochromatosis.
Phatak PD; Guzman G; Woll JE; Robeson A; Phelps CE
Arch Intern Med; 1994 Apr; 154(7):769-76. PubMed ID: 8147681
[TBL] [Abstract][Full Text] [Related]
5. Hereditary hemochromatosis screening: effect of mutation penetrance and prevalence on cost-effectiveness of testing algorithms.
Gagné G; Reinharz D; Laflamme N; Adams PC; Rousseau F
Clin Genet; 2007 Jan; 71(1):46-58. PubMed ID: 17204047
[TBL] [Abstract][Full Text] [Related]
6. [Cost-effectiveness evaluation of predictive molecular diagnostics using the example of hereditary non-polyposis colorectal cancer (HNPCC)].
Hagen A; Hessabi HK; Gorenoi V; Schönermark MP
Gesundheitswesen; 2008 Jan; 70(1):18-27. PubMed ID: 18273760
[TBL] [Abstract][Full Text] [Related]
7. [Using value of information analysis in decision making about applied research. The case of genetic screening for hemochromatosis in Germany].
Rogowski WH; Grosse SD; Meyer E; John J; Palmer S
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2012 May; 55(5):700-9. PubMed ID: 22526859
[TBL] [Abstract][Full Text] [Related]
8. [Cost-effectiveness analysis of a genetic screening program in the close relatives of Spanish patients with familial hypercholesterolemia].
Oliva J; López-Bastida J; Moreno SG; Mata P; Alonso R
Rev Esp Cardiol; 2009 Jan; 62(1):57-65. PubMed ID: 19150015
[TBL] [Abstract][Full Text] [Related]
9. Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection.
Sroczynski G; Esteban E; Conrads-Frank A; Schwarzer R; Mühlberger N; Wright D; Zeuzem S; Siebert U
Eur J Public Health; 2009 Jun; 19(3):245-53. PubMed ID: 19196737
[TBL] [Abstract][Full Text] [Related]
10. Genetic screening for iron overload: No evidence of discrimination at 1 year.
Hall MA; Barton JC; Adams PC; McLaren CE; Reiss JA; Castro O; Ruggiero A; Acton RT; Power TE; Bent TC
J Fam Pract; 2007 Oct; 56(10):829-34. PubMed ID: 17908514
[TBL] [Abstract][Full Text] [Related]
11. Screening for hemochromatosis in children of homozygotes: prevalence and cost-effectiveness.
Adams PC; Kertesz AE; Valberg LS
Hepatology; 1995 Dec; 22(6):1720-7. PubMed ID: 7489980
[TBL] [Abstract][Full Text] [Related]
12. Hemochromatosis screening in asymptomatic ambulatory men 30 years of age and older.
Baer DM; Simons JL; Staples RL; Rumore GJ; Morton CJ
Am J Med; 1995 May; 98(5):464-8. PubMed ID: 7733125
[TBL] [Abstract][Full Text] [Related]
13. Should female relatives of factor V Leiden carriers be screened prior to oral contraceptive use? A cost-effectiveness analysis.
Smith KJ; Monsef BS; Ragni MV
Thromb Haemost; 2008 Sep; 100(3):447-52. PubMed ID: 18766261
[TBL] [Abstract][Full Text] [Related]
14. A cost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy.
Ingles J; McGaughran J; Scuffham PA; Atherton J; Semsarian C
Heart; 2012 Apr; 98(8):625-30. PubMed ID: 22128210
[TBL] [Abstract][Full Text] [Related]
15. The German Coronary Artery Disease Risk Screening Model: development, validation, and application of a decision-analytic model for coronary artery disease prevention with statins.
Stollenwerk B; Gerber A; Lauterbach KW; Siebert U
Med Decis Making; 2009; 29(5):619-33. PubMed ID: 19773581
[TBL] [Abstract][Full Text] [Related]
16. Screening for hemochromatosis: phenotype versus genotype.
Edwards CQ; Griffen LM; Ajioka RS; Kushner JP
Semin Hematol; 1998 Jan; 35(1):72-6. PubMed ID: 9460810
[TBL] [Abstract][Full Text] [Related]
17. [Should we support large-scale screening for genetic haemochromatosis in France?].
Deugnier Y; Le Gall JY
Bull Acad Natl Med; 2004; 188(2):265-72; discussion 272-3. PubMed ID: 15506717
[TBL] [Abstract][Full Text] [Related]
18. Factors affecting the uptake of screening: a randomised controlled non-inferiority trial comparing a genotypic and a phenotypic strategy for screening for haemochromatosis.
Patch C; Roderick P; Rosenberg W
J Hepatol; 2005 Jul; 43(1):149-55. PubMed ID: 15876471
[TBL] [Abstract][Full Text] [Related]
19. Implementation of HaemScreen, a workplace-based genetic screening program for hemochromatosis.
Nisselle AE; Delatycki MB; Collins V; Metcalfe S; Aitken MA; du Sart D; Halliday J; Macciocca I; Wakefield A; Hill V; Gason A; Warner B; Calabro V; Williamson R; Allen KJ
Clin Genet; 2004 May; 65(5):358-67. PubMed ID: 15099342
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of hemochromatosis in the Puerto Rico veteran population.
Pérez R; Toro D; Fournier J; Villanueva A
P R Health Sci J; 2007 Jun; 26(2):147-50. PubMed ID: 17722428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
